XTX Topco’s Damora Therapeutics DMRA Stock Holding History

XTX Topco’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$561K	Buy	21,584 +11,856	+122%	+$287K	0.01%	2343
2026 Q1	$252K	Buy	+9,728	New	+$250K	﹤0.01%	2635
2024 Q2	–	Sell	-730	Closed	-$14.2K	–	2084
2024 Q1	$14.2K	Buy	+730	New	+$13K	﹤0.01%	1641
2023 Q4	–	Sell	-692	Closed	-$12.5K	–	1774
2023 Q3	$12.5K	Buy	+692	New	+$27.2K	﹤0.01%	1414
2021 Q3	–	Sell	-441	Closed	-$56K	–	811
2021 Q2	$56K	Buy	+441	New	+$60.1K	0.02%	721

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

XTX Topco's DMRA Position: Q2 2026 in Review

XTX Topco increased its Damora Therapeutics (DMRA) stake by 122% in Q2 2026, buying an estimated $287K and bringing the position to 21,584 shares worth $561K. The position accounts for 0.01% of the portfolio, ranked #2343.

XTX Topco first reported a position in DMRA in Q2 2021 and has held it in 5 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

XTX Topco held 21,584 shares of Damora Therapeutics worth $561K as of Q2 2026.
XTX Topco bought 11,856 Damora Therapeutics shares in Q2 2026, an estimated $287K.
Damora Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2343 holding.
XTX Topco first reported a position in Damora Therapeutics in Q2 2021 and has held it in 5 quarters since.
104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.